C‐terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by c‐jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma

Karen M.F. Sze, Glanice K.Y. Chu, Joyce M.F. Lee, Irene O.L. Ng – 23 July 2012 – Random integration of hepatitis B virus (HBV) DNA into the host genome is frequent in human hepatocellular carcinoma (HCC) and this leads to truncation of the HBV DNA, particularly at the C‐terminal end of the HBV X protein (HBx). In this study, we investigated the frequency of this natural C‐terminal truncation of HBx in human HCCs and its functional significance. In 50 HBV‐positive patients with HCC, full‐length HBx was detected in all nontumorous livers.

Scavenger receptor a restrains T‐cell activation and protects against concanavalin A‐induced hepatic injury

Daming Zuo, Xiaofei Yu, Chunqing Guo, Hongxia Wang, Jie Qian, Huanfa Yi, Xiao Lu, Zhi‐Ping Lv, John R. Subjeck, Huiping Zhou, Arun J. Sanyal, Zhengliang Chen, Xiang‐Yang Wang – 23 July 2012 – Negative feedback immune mechanisms are essential for maintenance of hepatic homeostasis and prevention of immune‐mediated liver injury. We show here that scavenger receptor A (SRA/CD204), a pattern recognition molecule, is highly up‐regulated in the livers of patients with autoimmune or viral hepatitis, and of mice during concanavalin A (Con A)‐induced hepatitis (CIH).

A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation

Gregory T. Everson, Norah A. Terrault, Anna S. Lok, Del R. Rodrigo, Robert S. Brown, Sammy Saab, Mitchell L. Shiffman, Abdullah M.S. Al‐Osaimi, Laura M. Kulik, Brenda W. Gillespie, James E. Everhart, and the Adult‐to‐Adult Living Donor Liver Transplantation Cohort Study – 23 July 2012 – Hepatitis C virus (HCV) infection recurs in liver recipients who are viremic at transplantation. We conducted a randomized, controlled trial to test the efficacy and safety of pretransplant pegylated interferon alpha‐2b plus ribavirin (Peg‐IFN‐α2b/RBV) for prevention of post‐transplant HCV recurrence.

Subscribe to